Accueil>>Signaling Pathways>> Others>>Anti-hypertensive sulfonanilide 1

Anti-hypertensive sulfonanilide 1

Catalog No.GC33770

Le sulfonanilide antihypertenseur 1 est un puissant antihypertenseur extrait du brevet EP0338793A2, composé XVIIIa,b*, exemple n°1.

Products are for research use only. Not for human use. We do not sell to patients.

Anti-hypertensive sulfonanilide 1 Chemical Structure

Cas No.: 129280-22-4

Taille Prix Stock Qté
1mg
534,00 $US
En stock
5mg
1 057,00 $US
En stock
10mg
1 801,00 $US
En stock
20mg
3 171,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Anti-hypertensive sulfonanilide 1 is a potent antihypertensive agent extracted from patent EP0338793A2, compound XVIIIa,b*, example No.1.

Anti-hypertensive sulfonanilide 1 can be classified as tetralin sulfonanilides, is found to have antihypertensive properties and is therefore useful in controlling elevated blood pressure in mammals such as humans. The effective antihypertensive amount for use will vary both with the route of administration, the condition under treatment and the mammal undergoing treatment, and is ultimately at the discretion of the physician. A suitable oral dose of the active compound for a mammal is in the range of from about 1 to about 50 mg per kilogram body weight per day; preferably from about 2 to about 20 mg/kg[1].

[1]. Mcdermed J, et al. Anti-hypertensive sulfonanilides. EP0338793A2.

Avis

Review for Anti-hypertensive sulfonanilide 1

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Anti-hypertensive sulfonanilide 1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.